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Background: TYRO3 is a member of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family and
functions to limit type 2 immune responses implicated in allergic sensitization. Recent studies have
shown that multiple intronic variants of TYRO3 were associated with asthma, implying that genetic
variation could contribute to errant immune activation. We therefore hypothesized that expression
quantitative trait loci (eQTLs) of the TYRO3 gene inﬂuence the development of allergic diseases (including
asthma and allergic rhinitis) in Japanese populations.
Methods: We performed a candidate gene caseecontrol association study of 8 eQTLs of TYRO3 on atopy,
asthma, and allergic rhinitis using 1168 unrelated Japanese adults who had GWAS genotyping. We then
examined the genetic impact of rs2297377 (TYRO3) on atopy and allergic rhinitis in 2 other independent
Japanese populations.
Results: A meta-analysis of 3 Japanese populations (a total of 2403 Japanese adults) revealed that
rs2297377 was associated with atopy and allergic rhinitis (OR ¼ 1.29 and 1.31; P ¼ 0.00041 and 0.0010,
respectively). The risk allele at rs2297377 correlated with decreased expression of TYRO3 mRNA. The
geneegene interaction between HLA-DPB1 and TYRO3 was not signiﬁcant with regard to sensitization.
The estimated proportion of atopy and allergic rhinitis cases attributable to the risk genotype was 14%
and 16%, respectively.
Conclusions: Our study identiﬁed TYRO3 as an important susceptibility gene to atopy and allergic rhinitis
in Japanese.
Copyright © 2018, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Type 2 immune responses, characterized by the differentia-
tion of CD4þ T helper type 2 (Th2) cells and the production of
type 2 cytokines such as interleukin-4 (IL-4), IL-5, IL-9 and IL-13,
play a critical role in the pathobiology of allergic diseases such as
asthma and allergic rhinitis. Recently, genome-wide associationMedicine, Division of Clinical
a, 1-1-1 Tennodai, Tsukuba,
asuko).
ety of Allergology.
rgology. Production and hosting by Elsestudies have revealed a link between the TYRO3 gene and
asthma in African American and Latino patients.1 TYRO3 is a
member of the TAM (TYRO3, AXL, and MERTK) family of receptor
tyrosine kinases expressed on dendritic cells and its activation
functions as a negative regulator of type 2 immune responses
that mediate both immunoactivation and immunopathology.1 In
this study, to examine the genetic impact of TYRO3 on the
development of atopy, asthma and allergic rhinitis in Japanese
individuals, we performed a candidate gene caseecontrol as-
sociation study on 2403 samples from 3 independent Japanese
populations. We also assessed the contribution of TYRO3 in
estimating the population-attributable risk for the general
Japanese population.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Ethics statement
This study was approved by the Human Genome Analysis and
Epidemiology Research Ethics Committee of the University of
Tsukuba plus the Human Genome/Gene Analysis Research Ethics
Review Committees of the Tsukuba Medical Center and RIKEN.
Written, informed consent was obtained from each participant
before the investigation in accordance with the principles of the
Declaration of Helsinki.
Participant pools
We studied 3 Japanese adult populations. All participants were
unrelated Japanese adults, recruited within Ibaraki Prefecture,
Japan from June 2008 to March 2016. The ﬁrst population (Tsukuba
Cohort 1) consisted of 201 patients with asthma and 967 healthy
adults. In this population, all participants had genome-wide SNP
typing.2 The second population (Tsukuba Cohort 2) consisted of 190
patients with asthma and 514 healthy adults.3,4 In these 2 pop-
ulations, asthmatic patients were recruited from the Tsukuba Uni-
versity Hospital and its afﬁliated hospitals. Healthy adults without
respiratory diseases were recruited from persons who visited the
Tsukuba Medical Center for annual health checkups. Patients were
considered asthmatic on the basis of recurrent episodes of two or
more of the three symptoms (coughing, wheezing, or dyspnea)
associatedwith demonstrable reversible airﬂow obstruction and/or
increased airway responsiveness to methacholine.5 Healthy adults
in both populations had no pulmonary diseases such as asthma or
COPD. Atopy was assessed by measurement of speciﬁc IgE
responsiveness to 14 common inhaled allergens including Derma-
tophagoides farinae, grass pollens, animal dander, and molds. We
deﬁned atopy as a positive response to at least 1 of the 14 allergens.
Allergic rhinitis was deﬁned as the presence of paroxysms of one or
more of three symptoms (sneezing, rhinorrhea, or nasal obstruc-
tion) with atopy.6
The third population consisted of 531 students (102 patients
with asthma) enrolled in medicine, nursing or medical sciences at
the University of Tsukuba from 2013 to 2015 (Tsukuba Student
Cohort).7 In this population, allergen-speciﬁc IgE antibody was
measured only for Japanese cedar pollen and D. farinae by the CAP-
FEIA method (Phadia AB, Uppsala, Sweden). Atopy was deﬁned by
the presence of speciﬁc IgE antibody towards either D. farinae or
Japanese cedar and the diagnosis of allergic rhinitis was based on
the presence of both atopy and nasal symptoms (sneezing, rhi-
norrhea, or nasal obstruction). Asthmatic patients were excluded
from analyses of atopy and allergic rhinitis since atopy is secondary
to asthma in some individuals and, as it is not a primary driver
of the disease,8 its presence could confound the genetic analysis
results.
Genotyping
Genomic DNAwas extracted fromwhole blood by an automated
DNA extraction system (QuickGene-610L; Fujiﬁlm, Tokyo, Japan). In
Tsukuba Cohort 1, 201 patients with asthma and 967 healthy con-
trol adults underwent GWAS genotyping using Illumina HumanHap
550k v3/610-Quad BeadChips (Illumina, San Diego, CA, USA) as
described previously.2 The TaqMan allele-speciﬁc ampliﬁcation
method was used to deﬁne genotypes for rs2297377 in both Tsu-
kuba Cohort 2 and the Tsukuba Student Cohort (Applied Bio-
systems, Foster City, CA, USA).Statistical analysis
SNPs in and around the TYRO3 gene were examined for associ-
ations with allergic diseases using logistic regression modeling. For
rs2297377, combined results from 3 independent cohorts were
analyzed by adjusting for the cohort in a logistic regression model.
To quantify the effect of heterogeneity according to the population,
we also calculated the I2 heterogeneity index using PLINK ver. 1.07
(Command:–meta-analysis), which describes the percentage of
total variation across populations that is due to heterogeneity
rather than chance.9 HardyeWeinberg equilibrium was conﬁrmed
for the genotype frequencies of the 3 populations.
The population attributable risk fractions (PARF) for atopy and
allergic rhinitis were examined using the following formula:
PARF ¼ P(E) (OR-1)/[1 þ P(E) (OR-1)], where P(E) is the probability
of exposure, in this case the probability of having the risk genotype,
and OR refers to the odds of having atopy and allergic rhinitis for
individuals with the risk genotype as opposed to the odds of having
atopy and allergic rhinitis for individuals with non-risk genotypes.
All analyseswere performed in SPSS (version 24). P values of less
than 0.05 were considered statistically signiﬁcant. Given that there
were a priori reasons for suspecting the TYRO3 gene would be
linked to allergic disease risk, our data were not corrected for
multiple testing.
Results
Lung tissue shows eQTLs are associated with TYRO3 mRNA
expression
The characteristics of Tsukuba Cohort 1, Tsukuba Cohort 2 and
the Tsukuba Student Cohort are shown in Table 1. The strongest
association with asthma in the previous meta-analysis of non-
Japanese GWAS was found with rs1200341.1 However, the minor
allele frequency (MAF) of this SNP was found to be very rare (0.8%)
in Tsukuba Cohort 1. As variation in gene expression is an important
exploitative mechanism to boost statistical power and enhance
interpretation in genome-wide association studies (GWASs) of
underlying susceptibility to complex diseases,10 we initially
searched cis-eQTLs of TYRO3 that reside within 1 Mb of the tran-
scription start site on the TYRO3 genewith the GTEx Portal database
(https://gtexportal.org/home/). A total of 192 SNPs associated with
lung levels of TYRO3mRNAwere found of which 8 were selected for
genetic analyses. Criteria for these analyses were strong association
with TYRO3 mRNA expression in lung tissues, P values of less than
5  1010, and a MAF of more than 10% in the HapMap-JPT (Japa-
nese in Tokyo, Japan, Phase 3) (Table 2).
TYRO3 eQTLs are associated with allergic diseases
In Tsukuba Cohort 1, rs2297377 was associated with atopy
(p ¼ 0.043) and allergic rhinitis (p ¼ 0.019) while rs1473781 was
associated with allergic rhinitis (p ¼ 0.033) (Table 2). None of the 8
chosen SNPs were associated with the presence of asthma even
when the analysis was restricted to atopic asthma (Table 2). Given
that rs2297377 showed the strongest signiﬁcant association with
atopy and allergic rhinitis, we then examined these associations in
both Tsukuba Cohort 2 and the Tsukuba Student Cohort. In Tsukuba
Cohort 2, rs2297377 was again associated with atopy and allergic
rhinitis (OR ¼ 1.44 and 1.46; p ¼ 0.0059 and 0.016, respectively)
(Table 3). In the Tsukuba Student Cohort, rs229377 was associated
with atopy when the carrier of the risk allele was compared with
non-carriers (OR ¼ 2.13; p ¼ 0.026). In the combined meta-analysis
Table 1
Characteristics of study population.
Tsukuba cohort 1 Tsukuba cohort 2 Tsukuba student cohort
nonasthmatics asthmatics nonasthmatics asthmatics nonasthmatics asthmatics
Number of subjects 967 201 514 190 429 102
Sex (female, %) 526 (54.4) 118 (58.7) 263 (51.2) 117 (61.9) 257 (59.9) 60 (58.8)
Age, y (range) 50.0 (27e74) 51.0 (20e72) 51.2 (22e81) 56.8 (18e84) 19.8 (18e38) 19.9 (19e29)
Age of asthma onset (range) 36.9 (0e70) 39.1 (1e82) NA
Smoking (%)
Pack-year
0 607 (62.8) 164 (82.0) 309 (60.1) 122 (64.2) NA NA
0e10 127 (13.1) 33 (16.5) 64 (12.5) 21 (11.1) NA NA
>10 233 (24.1) 3 (1.5) 141 (27.4) 46 (24.2) NA NA
Atopy (%) 541 (55.9) 143 (71.1) 328 (63.8) 137 (72.1) 334 (77.9) 94 (92.2)
Allergic rhinitis (%) 358 (37.0) 69 (34.3) 207 (40.3) 36 (18.9) 163 (67.9) 60 (58.8)
Serum IgE (log, SD) 1.73 (0.56) 2.23 (0.62) 1.93 (0.64) 2.26 (0.60) 2.15 (0.61) 2.47 (0.63)
Information on asthma onset age and smoking was missing in 3 and 1 patients with asthma in the Tsukuba cohort 2, respectively.
Information on serum IgE was missing in 2 and 4 patients with asthma in the Tsukuba cohort 1 and 2, respectively.
Table 2
Association of eQTL SNPs of TYRO3 with allergic diseases in Tsukuba cohort 1.
SNP P value Minor allele Minor allele frequency P value
eQTL HapMap JPT Tsukuba cohort 1 (nonasthmatics þ asthmatics) Asthma Atopy Allergic rhinitis
rs9944249 7.0  1034 T 0.15 0.14 0.39 0.52 0.44
rs721772 6.4  1024 A 0.44 0.39 0.92 0.89 0.51
rs2297381 1.3  1023 C 0.44 0.40 0.77 0.76 0.33
rs1200345 1.7  1017 T 0.33 0.30 0.73 0.19 0.12
rs1473781 1.9  1017 A 0.16 0.14 0.52 0.14 0.033
rs1200353 1.0  1015 T 0.15 0.13 0.68 0.18 0.095
rs2297380 1.8  1015 T 0.40 0.41 0.86 0.42 0.15
rs2297377 1.5  1014 A 0.31 0.32 0.38 0.043 0.019
Signiﬁcant differences are highlighted in bold (p< 0.05).
Table 3
Results of association analysis in 3 populations and meta-analysis (rs2297377).
Tsukuba cohort 1 Tsukuba cohort 2 Tsukuba student cohort Meta-analysis
n RAF OR P value n RAF OR P value n RAF OR P value OR P value
(G) (95% CI) (G) (95% CI) (G) (95% CI) (95% CI)
Asthmatics 201 0.66 0.91 0.38 190 0.65 0.89 0.35 102 0.65 0.94 0.70 0.91 0.19
Nonasthmatics 967 0.68 (0.72e1.13) 514 0.68 (0.70e1.14) 429 0.66 (0.68e1.30) (0.78e1.05)
Atopy () 426 0.66 1.22 0.043 186 0.62 1.44 0.0059 95 0.62 1.27 0.17 1.29 0.00041
Atopy (þ) 541 0.70 (1.01e1.47) 328 0.71 (1.11e1.87) 334 0.67 (0.90e1.81) (1.12e1.48)
Allergic rhinitis () 370 0.66 1.30 0.019 152 0.63 1.46 0.016 77 0.64 1.14 0.53 1.31 0.0010
Allergic rhinitis (þ) 358 0.72 (1.04e1.61) 207 0.72 (1.07e1.99) 163 0.67 (0.76e1.70) (1.12e1.55)
RAF, risk allele frequency.
Signiﬁcant differences are highlighted in bold (p< 0.05).
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found to be associated with atopy and allergic rhinitis (OR ¼ 1.29
and 1.31; P ¼ 0.00041 and 0.0010, respectively) (Table 3) while the
risk allele G that is associated with the presence of atopy and
allergic rhinitis was signiﬁcantly correlated with decreased
expression of TYRO3 mRNA in the lung. I2 was 0 for asthma (p for
Cochrane's Q statistic ¼ 0.97), allergic sensitization (0.58) and/or
allergic rhinitis (0.62), revealing that there is no clear heterogeneity
according to the population for the association between rs2297377
and atopy or allergic rhinitis.Geneegene interaction between HLA-DPB1 and TYRO3 is not
signiﬁcant with regard to allergic sensitization
Dendritic cells (DCs) present peptide antigen via MHC class II to
stimulate naïve T cells and effect an active response while TYRO3,interacting with Protein S on the DCs, engages a negative feedback
mechanism that speciﬁcally inhibits type 2 inﬂammation.11 As the
signiﬁcance of associations between HLA-DPB1 genotypes and Jap-
anese cedar sensitization was previously established,7 we therefore
examined this pushepull relationship by studying the genetic in-
ﬂuence of TYRO3 on the signiﬁcance of associations between HLA-
DPB1 genotypes and Japanese cedar sensitization in the Tsukuba
student cohort. We found that the effect of rs229377 genotype on
the effects of HLA-DPB1 alleles with regard to allergic sensitization
was not signiﬁcant (p > 0.1 for interaction term) (Table 4).rs229377 population attributable risk for atopy and allergic rhinitis
In the estimation of the population attributable risk fraction
(PARF) for atopy and allergic rhinitis, we used a recessive model
that provided a better ﬁt than dominant modeling as revealed by
Table 4
The interaction of rs2297377 genotype with HLA-DPB1 allele.
rs2297377
genotype
JC sensitization
(%)
HLA-DPB1*02 HLA-DPB1*05
Frequency
(%)
Case
Count (%)
Control
Count (%)
P value OR (95% CI) Frequency
(%)
Case
Count (%)
Control
Count (%)
P value OR (95% CI)
Total (n ¼ 429) 308 (71.8) 24.9 134 (21.8) 80 (33.1) 0.00082 0.57 (0.41e0.79) 39.2 253 (41.1) 83 (34.3) 0.10 1.28 (0.95e1.73)
AA (n ¼ 42) 24 (57.1) 22.6 8 (16.7) 11 (30.6) 0.14 0.44 (0.15e1.31) 35.7 17 (35.4) 13 (36.1) 0.95 0.97 (0.39e2.43)
AG (n ¼ 207) 155 (74.9) 26.1 74 (23.9) 34 (32.7) 0.079 0.64 (0.39e1.05) 39.6 127 (41.0) 37 (35.6) 0.35 1.24 (0.79e1.94)
GG (n ¼ 180) 129 (71.7) 24.2 52 (20.2) 35 (34.3) 0.0077 0.50 (0.30e0.83) 37.8 109 (42.2) 33 (32.4) 0.10 1.47 (0.93e2.33)
P for interaction ¼ 0.42 P for interaction ¼ 0.72
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of atopic and allergic rhinitis cases statistically attributable to the
rs229377 G allele at TYRO3 was 14% and 16%, respectively, in our
Japanese populations.
Discussion
In the current study, we have shown the importance of the
TYRO3 functional polymorphism that alters gene expression in the
pathogenesis of allergic sensitization and allergic rhinitis. Our
meta-analysis of 3 independent Japanese populations showed that
the rs2297377 at the TYRO3 is negatively associated with the
development of allergic sensitization and allergic rhinitis. The
exact mechanism for this is unclear but the evidence points to the
lack of TAM family receptor tyrosine kinase TYRO3 expression in
lung dendritic cells (DCs) which drives enhanced production of
type 2 chemokines and an exacerbated type 2 immune response.1
Our ﬁndings in the current study, therefore, suggest that the
mutated TYRO3 genotype that correlates with lower mRNA
expression leads to an enhanced type 2 immunity which subse-
quently results in an increased susceptibility to allergic sensitiza-
tion and allergic rhinitis.
It is of interest to note that, when the microarray analysis was
conducted on mouse bone marrowederived cultured mast cells
(MCs) in the presence of IL-33 for 4 weeks, TYRO3 was strongly
upregulated.12 It is suggested that IL-33 has some role in resolution
of the exaggerated type-2 immune response by tempering further
MC-dependent allergic inﬂammation under chronic conditions.12
Therefore, the failure of IL-33 to downregulate MC activation
through insufﬁcient expression of a negative regulator of type 2
immune responses, TYRO3, may at least partly explain our ﬁndings
of the association between rs2297377 and allergic sensitization.
The original meta-analysis of GWAS identiﬁed TYRO3 as a sus-
ceptibility gene to asthma.1 In our study, however, rs2297377 was
not associated with asthma and this discrepancy may be partly
explained by the heterogeneity of asthma. First of all, patients with
asthma in the original GWAS were predominantly early-onset and
atopic.13,14 In contrast, in both Tsukuba cohorts (1 and 2), the me-
dian of asthma onset age was approximately 38 years old and the
presence of atopy in patients with asthma was less frequent
(approximately 72%) compared to the original study. In addition,
given that the TAM family also functions as an apoptotic cell
recognition receptor (controlling the duration of the immune
response) and given that apoptotic cell removal is defective in non-
eosinophilic asthma,15 dysregulated activation of apoptotic cell
recognition receptors may rather exaggerate inﬂammatory re-
sponses leading to subsequent development of asthma in certain
disease subtypes. We believe that the genetic impact of TYRO3
therefore needs to be examined in larger populations with a focus
on speciﬁc asthma phenotypes.
We acknowledge several limitations of our study. The homo-
geneity of our study populations may limit the applicability of our
results to populations of different ancestries. Lack of populationdiversity might also increase the size of LD blocks and thereby limit
the resolution with which true regulatory sites can be identiﬁed. In
addition, a false-positive result may serve as an alternate expla-
nation for the modest association of TYRO3 with allergic sensiti-
zation and allergic rhinitis in our study. Possible explanations for a
false-positive result may include technical artifacts, population
stratiﬁcation, or an inappropriate statistical threshold of signiﬁ-
cance but our genotyping efﬁciency and accuracy argue strongly
against technical artifacts. Additionally, all cohorts were comprised
of Japanese adults recruited in Ibaraki Prefecture, Japan which re-
duces the likelihood of stratiﬁcation. Ultimately, additional studies
in sufﬁciently powered cohorts of patients with allergic diseases,
together with stratiﬁcation according to disease phenotypes, are
required to deﬁnitively determine whether genetic variations
within TYRO3 inﬂuence the risk of developing allergic diseases.
Finally, it is clear that studies attempting to accurately deﬁne
population-attributable risks for a speciﬁc polymorphism in risk
genes for common polygenic disorders (such as allergies) will
require very large study populations.
In conclusion, our ﬁndings provide deeper insight into the ge-
netic contribution of TYRO3 in the development of allergic diseases
in Japanese populations. Given its population risk attribution of
more than 10% for atopy and allergic rhinitis, TYRO3 may be an
attractive pharmacological target for treating allergic diseases such
as Japanese cedar pollinosis.
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